Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 60900 [2018-25872]
Download as PDF
<![CDATA[
60900
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
The company plans to manufacture
bulk synthetic active pharmaceutical
ingredients (APIs) for product
development and distribution to its
customers. No other activity for these
drug codes are authorized for this
registration.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25862 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
DATES:
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 27, 2018. Such
persons may also file a written request
for a hearing on the application on or
before December 27, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
September 27, 2018, Fisher Clinical
Services, Inc., 700A–C Nestle Way,
Breinigsville, Pennsylvania 18031, has
applied to be registered as an importer
of the below listed basic classes of
controlled substances listed in schedule
I & II.
Controlled substance
Drug code
Psilocybin .................................................................................................................................................................
Methylphenidate .......................................................................................................................................................
Levorphanol .............................................................................................................................................................
Noroxymorphone .....................................................................................................................................................
Tapentadol ...............................................................................................................................................................
The company plans to import the
listed controlled substances for
analytical research, testing, and clinical
trials. This authorization does not
extend to the import of a finished FDA
approved or non-approved dosage form
for commercial distribution in the
United States.
DEPARTMENT OF JUSTICE
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
ACTION:
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Cayman
Chemical Company
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 28, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
DATES:
[FR Doc. 2018–25872 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
amozie on DSK3GDR082PROD with NOTICES1
Drug Enforcement Administration
Jkt 247001
PO 00000
Frm 00080
Fmt 4703
I
II
II
II
II
Drug code
3-Fluoro-N-methylcathinone (3–FMC) .......................................................................................................................
Cathinone ...................................................................................................................................................................
Methcathinone ............................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .......................................................................................................................
17:45 Nov 26, 2018
7437
1724
9220
9668
9780
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 25,
2018, Cayman Chemical Company, 1180
East Ellsworth Road, Ann Arbor,
Michigan 48108 applied to be registered
as a bulk manufacturer for the basic
classes of controlled substances:
Controlled substance
VerDate Sep<11>2014
Schedule
Sfmt 4703
E:\FR\FM\27NON1.SGM
27NON1
1233
1235
1237
1238
Schedule
I
I
I
I
]]>Agencies
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Page 60900]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25872]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before December 27, 2018.
Such persons may also file a written request for a hearing on the
application on or before December 27, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
September 27, 2018, Fisher Clinical Services, Inc., 700A-C Nestle Way,
Breinigsville, Pennsylvania 18031, has applied to be registered as an
importer of the below listed basic classes of controlled substances
listed in schedule I & II.
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin.............................. 7437 I
Methylphenidate......................... 1724 II
Levorphanol............................. 9220 II
Noroxymorphone.......................... 9668 II
Tapentadol.............................. 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical research, testing, and clinical trials. This authorization
does not extend to the import of a finished FDA approved or non-
approved dosage form for commercial distribution in the United States.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-25872 Filed 11-26-18; 8:45 am]
BILLING CODE 4410-09-P
